Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations

Triclabendazole is a poorly-water soluble (0.24 μg/mL) compound classified into the Class II/IV of the Biopharmaceutical Classification System. It is the drug of choice to treat fascioliasis, a neglected parasitic disease worldwide disseminated. Triclabendazole is registered as veterinary medicine a...

ver descrição completa

Detalhes bibliográficos
Autores: Real, Daniel Andres, Hoffmann, Stefan, Leonardi, Darío, Salomon, Claudio Javier, Goycoolea, Francisco M.
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2018
País:Argentina
Recursos:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositório:CONICET Digital (CONICET)
Idioma:inglês
OAI Identifier:oai:ri.conicet.gov.ar:11336/87178
Acesso em linha:http://hdl.handle.net/11336/87178
Access Level:Acceso aberto
Palavra-chave:CHITOSAN
NANODELIVERY
TRICLABENDAZOLE
https://purl.org/becyt/ford/1.4
https://purl.org/becyt/ford/1
id AR_978f1dfd7af02e09aa2f2fe62a6488a8
oai_identifier_str oai:ri.conicet.gov.ar:11336/87178
network_acronym_str AR
network_name_str Argentina
repository_id_str
dc.title.none.fl_str_mv Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
title Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
spellingShingle Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
Real, Daniel Andres
CHITOSAN
NANODELIVERY
TRICLABENDAZOLE
https://purl.org/becyt/ford/1.4
https://purl.org/becyt/ford/1
title_short Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
title_full Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
title_fullStr Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
title_full_unstemmed Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
title_sort Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
dc.creator.none.fl_str_mv Real, Daniel Andres
Hoffmann, Stefan
Leonardi, Darío
Salomon, Claudio Javier
Goycoolea, Francisco M.
author Real, Daniel Andres
author_facet Real, Daniel Andres
Hoffmann, Stefan
Leonardi, Darío
Salomon, Claudio Javier
Goycoolea, Francisco M.
author_role author
author2 Hoffmann, Stefan
Leonardi, Darío
Salomon, Claudio Javier
Goycoolea, Francisco M.
author2_role author
author
author
author
dc.subject.none.fl_str_mv CHITOSAN
NANODELIVERY
TRICLABENDAZOLE
https://purl.org/becyt/ford/1.4
https://purl.org/becyt/ford/1
topic CHITOSAN
NANODELIVERY
TRICLABENDAZOLE
https://purl.org/becyt/ford/1.4
https://purl.org/becyt/ford/1
description Triclabendazole is a poorly-water soluble (0.24 μg/mL) compound classified into the Class II/IV of the Biopharmaceutical Classification System. It is the drug of choice to treat fascioliasis, a neglected parasitic disease worldwide disseminated. Triclabendazole is registered as veterinary medicine and it is only available for human treatment as 250 mg tablets. Thus, the aim of this work was to develop novel drug delivery systems based on nanotechnology approaches. The chitosan-based nanocapsules and nanoemulsions of triclabendazole were fully characterized regarding their particle size distribution, polydispersity index and zeta potential, in-vitro release and stability in biological media. Cytotoxicity evaluation and cellular uptake studies using CaCo-2 cell line were also investigated. The results indicated an average hydrodynamic size around ∼160 nm were found for unloaded nanoemulsions which were slightly increased up to ∼190 nm for loaded one. In contrast, the average hydrodynamic size of the nanocapsules increased from ∼160 nm up to ∼400 nm when loaded with triclabendazole. The stability studies upon 30 days storage at 4, 25 and 37°C showed that average size of nanoemulsions was not modified with varying amounts of loaded TCBZ while an opposite result was seen in case of loaded nanocapsules. In addition, a slight reduction of zeta potential values over time was observed in both triclabendazole nanosystems. Release of TCBZ from nanoformulations over 6 h in simulated gastric fluid was 9 to 16-fold higher than with untreated TCBZ dispersion. In phosphate buffer saline solution there was no drug release for neither nanocapsules nor nanoemulsions. Cell viabilities studies indicated that at certain concentrations, drug encapsulation can lower its cytotoxic effects when compared to untreated drug. Confocal laser scanning microscopy study has shown that nanocapsules strongly interacted with Caco-2 cells in vitro which could increase the passage time of triclabendazole after oral administration. The results of this study constitute the first step towards the development of nanoformulations intended for the oral delivery of anti-parasitic drugs of enhanced bioavailability.
publishDate 2018
dc.date.none.fl_str_mv 2018-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/87178
Real, Daniel Andres; Hoffmann, Stefan; Leonardi, Darío; Salomon, Claudio Javier; Goycoolea, Francisco M.; Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations; Public Library of Science; Plos One; 13; 12; 12-2018; 1-17
1932-6203
CONICET Digital
CONICET
url http://hdl.handle.net/11336/87178
identifier_str_mv Real, Daniel Andres; Hoffmann, Stefan; Leonardi, Darío; Salomon, Claudio Javier; Goycoolea, Francisco M.; Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations; Public Library of Science; Plos One; 13; 12; 12-2018; 1-17
1932-6203
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0207625
info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0207625
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1799196090095894528
spelling Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulationsReal, Daniel AndresHoffmann, StefanLeonardi, DaríoSalomon, Claudio JavierGoycoolea, Francisco M.CHITOSANNANODELIVERYTRICLABENDAZOLEhttps://purl.org/becyt/ford/1.4https://purl.org/becyt/ford/1Triclabendazole is a poorly-water soluble (0.24 μg/mL) compound classified into the Class II/IV of the Biopharmaceutical Classification System. It is the drug of choice to treat fascioliasis, a neglected parasitic disease worldwide disseminated. Triclabendazole is registered as veterinary medicine and it is only available for human treatment as 250 mg tablets. Thus, the aim of this work was to develop novel drug delivery systems based on nanotechnology approaches. The chitosan-based nanocapsules and nanoemulsions of triclabendazole were fully characterized regarding their particle size distribution, polydispersity index and zeta potential, in-vitro release and stability in biological media. Cytotoxicity evaluation and cellular uptake studies using CaCo-2 cell line were also investigated. The results indicated an average hydrodynamic size around ∼160 nm were found for unloaded nanoemulsions which were slightly increased up to ∼190 nm for loaded one. In contrast, the average hydrodynamic size of the nanocapsules increased from ∼160 nm up to ∼400 nm when loaded with triclabendazole. The stability studies upon 30 days storage at 4, 25 and 37°C showed that average size of nanoemulsions was not modified with varying amounts of loaded TCBZ while an opposite result was seen in case of loaded nanocapsules. In addition, a slight reduction of zeta potential values over time was observed in both triclabendazole nanosystems. Release of TCBZ from nanoformulations over 6 h in simulated gastric fluid was 9 to 16-fold higher than with untreated TCBZ dispersion. In phosphate buffer saline solution there was no drug release for neither nanocapsules nor nanoemulsions. Cell viabilities studies indicated that at certain concentrations, drug encapsulation can lower its cytotoxic effects when compared to untreated drug. Confocal laser scanning microscopy study has shown that nanocapsules strongly interacted with Caco-2 cells in vitro which could increase the passage time of triclabendazole after oral administration. The results of this study constitute the first step towards the development of nanoformulations intended for the oral delivery of anti-parasitic drugs of enhanced bioavailability.Fil: Real, Daniel Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Hoffmann, Stefan. Westfalische Wilhelms Universitat; AlemaniaFil: Leonardi, Darío. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Salomon, Claudio Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Goycoolea, Francisco M.. University of Leeds; Reino UnidoPublic Library of Science2018-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/87178Real, Daniel Andres; Hoffmann, Stefan; Leonardi, Darío; Salomon, Claudio Javier; Goycoolea, Francisco M.; Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations; Public Library of Science; Plos One; 13; 12; 12-2018; 1-171932-6203CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0207625info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0207625info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2024-05-08T14:14:24Zoai:ri.conicet.gov.ar:11336/87178instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982024-05-08 14:14:24.375CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
score 15,811543

Registros relacionados